TELA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.59 below Tela Bio Inc average.
Within Medical Equipment & Supplies industry 91 other companies have achieved higher Quick Ratio than Tela Bio Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1044 to 1584.
TELA Bio Inc., a leading medical technology company, has recently announced an agreement to sell distribution rights for its innovative wound care product to MIMEDX. This promising development comes at a crucial time for TELA Bio, as the company faces both positive and negative shifts in its financial landscape. Financial Challenge: Increased Current Liabilities and Decreased Quick Ratio: In the third quarter of 2023, TELA Bio experienced a notable increase in Current Liabilities. As a consequence, the company s Quick Ratio fell to 3.8, now below the TELA Bio Inc average Quick Ratio. This decline is significant when compared to other companies within the industry, with 50 companies boasting higher Quick Ratios in the same period.
TELA Bio, Inc. (“TELA Bio”), a leading medical technology company committed to revolutionizing soft-tissue reconstruction solutions that prioritize the preservation and restoration of patients own anatomy, disclosed today the approval of inducement grants by the Compensation Committee of its Board of Directors. These restricted stock units, amounting to 5,500 shares of TELA Bio common stock, were awarded to nine recently hired employees. The grants were issued on January 18, 2024, in accordance with the Nasdaq Rule 5635(c)(4) inducement grant exception, serving as a vital component of each individual s employment compensation and an incentive for their acceptance of employment with TELA Bio. TELA Bio has established itself as a commercial-stage organization dedicated to providing cutting-edge medical technology solutions that optimize clinical outcomes. With a keen focus on soft-tissue reconstruction, the company aims to enhance patient experiences through the preservation and restoration of their unique anatomical structures. In alignment with their commitment to innovation, TELA Bio has successfully recruited a group of talented individuals who will contribute to the company s continued growth and success.
Introduction TELA Bio, a leading medical technology company specializing in soft-tissue reconstruction solutions, has recently announced its approval of inducement grants in the form of restricted stock units (RSUs). These grants, covering a total of 20,175 shares of common stock, have been offered to sixteen newly-hired employees and were deemed necessary to encourage their acceptance of employment with TELA Bio. The Compensation Committee of the Board of Directors of TELA Bio has sanctioned this move, in accordance with the Nasdaq Rule 5635(c)(4) inducement grant exception. TELA Bio s Commitment to Optimize Clinical Outcomes TELA Bio s primary focus is on providing innovative solutions for soft-tissue reconstruction that prioritize the preservation and restoration of patients own anatomical structures. With a commitment to optimizing clinical outcomes, TELA Bio aims to revolutionize the field of medical technology. These inducement grants signify the company s dedication to attracting and retaining top-tier talent, ensuring the continued advancement of their novel medical solutions.
On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2026 to $19.08 millions, cumulative Quick Ratio decreased to 2.09 below the average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Medical Equipment & Supplies industry 197 other companies have achieved higher Quick Ratio than Tela Bio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3036 to 3804.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
